Dangerous energy | Thermal energy,,one of surgery (The temperature of treatment site vs. body temperature) [1] | Treatment materials | |||||
---|---|---|---|---|---|---|---|
Radiotherapy | Higher temp (so-called local thermotherapy) | Lower temperature | Chemical ablation, embolization | Chemo-, targeted, hormone, immuno-therapy | |||
Ablation (> 50 ℃ or 800 V/cm) | Hyperthermia (2–5 V/cm or 41 ~ 45℃) | Cryo-ablation (− 20 to − 40℃) | |||||
[Noninvasive] | [Noninvasive] (LA, HIFU) | [Mini-invasive] (IRE,RF, MW) | [Noninvasive] (Electro-field) | [Mini-invasive] (MNPs) | [Mini-invasive] | [Mini-invasive] | |
(LA) < 100 μm size,800–1100 nm, 25 W; (HIFU) 1–5/20 MHz, 1,000 ~ 10,000 W/cm2 | (IRE)3000 V,50A, 250/500 kHz; (RF)350–500 kHz (MW)900–2500 MHz | 13.56 MHz, 40 W-150 W, 60/80 min. for several times | 0.02 − 1.1 MHz, 2–20 kAm−1, tens of minutes | − 140 ℃/ − 190 ℃, double freeze–thaw cycles (13–35 min.) | |||
• Many side effects • Combination with thermo-therapies [5] | • Surface or shallow depth • Limited treatment size/time (LA: 2 cm for 10 min; HIFU: 3.5 cm) | • Several hours wait for IRE impact • Limited treatment size (< 3 cm) /time | • Limited tumor specificity • Combination with chemo/ radiotherapies | • Limited to the regions without spreading away • Applied fields with healthy-risk specifics against 200 kHz or 5.0 × 109 am−1 s−1 | • The inability to control hemorrhage without intra-arterial access [22, 23] | • The inability to control position • Limited treatment effect • Combination with thermo-therapies | • Systematic treatment • Large individual difference • Induced/enhanced by thermo-therapies |